Your browser doesn't support javascript.
loading
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC.
Drilon, Alexander; Chiu, Chao-Hua; Fan, Yun; Cho, Byoung Chul; Lu, Shun; Ahn, Myung-Ju; Krebs, Matthew G; Liu, Stephen V; John, Thomas; Otterson, Gregory A; Tan, Daniel S W; Patil, Tejas; Dziadziuszko, Rafal; Massarelli, Erminia; Seto, Takashi; Doebele, Robert C; Pitcher, Bethany; Kurtsikidze, Nino; Heinzmann, Sebastian; Siena, Salvatore.
Afiliação
  • Drilon A; Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, New York.
  • Chiu CH; Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Fan Y; Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.
  • Cho BC; Division of Medical Oncology, Yonsei Cancer Center, Seoul, Republic of Korea.
  • Lu S; Department of Medical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
  • Ahn MJ; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Krebs MG; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie National Health Service (NHS) Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.
  • Liu SV; Georgetown University, Washington, District of Columbia.
  • John T; Department of Medical Oncology, Peter MacCallum Cancer Center, and Olivia Newton-John Cancer Centre, Austin Health, Melbourne, Australia.
  • Otterson GA; Arthur G. James Cancer Hospital, and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
  • Tan DSW; Division of Medical Oncology, National Cancer Centre Singapore, Duke-National University of Singapore (NUS) Medical School, Singapore.
  • Patil T; Division of Medical Oncology, Department of Medicine, University of Colorado, Aurora, Colorado.
  • Dziadziuszko R; Department of Oncology and Radiotherapy and Early Clinical Trials Center, Medical University of Gdansk, Gdansk, Poland.
  • Massarelli E; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California.
  • Seto T; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Doebele RC; Division of Medical Oncology, Department of Medicine, University of Colorado, Aurora, Colorado.
  • Pitcher B; F. Hoffmann-La Roche Ltd, Mississauga, Canada.
  • Kurtsikidze N; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Heinzmann S; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Siena S; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
JTO Clin Res Rep ; 3(6): 100332, 2022 Jun.
Article em En | MEDLINE | ID: mdl-35663414

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article